AZU1 ELISA kit
- Known as:
- AZU1 Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- DL-AZU1-Hu
- Product Quantity:
- 96T
- Category:
- Elisa Kits
- Supplier:
- WDSTD
- Gene target:
- AZU1 ELISA kit
Related genes to: AZU1 ELISA kit
- Gene:
- AZU1 NIH gene
- Name:
- azurocidin 1
- Previous symbol:
- -
- Synonyms:
- AZU, CAP37, AZAMP, HBP, NAZC, HUMAZUR
- Chromosome:
- 19p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1992-10-21
- Date modifiied:
- 2014-11-18
Related products to: AZU1 ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit(1-Kit) 14,15-EET DHET Hypertension ELISA Kit Related articles to: AZU1 ELISA kit
- Dipeptidyl peptidase-1 (DPP1) inhibitors prevent the activation of neutrophil serine proteases and reduce exacerbations in people with bronchiectasis. We previously identified a novel effect of DPP1 inhibitors in reducing the neutrophil pseudoenzyme azurocidin-1 (AZU1). The aim of this study was to investigate the role of AZU1 in the pathophysiology of bronchiectasis. - Source: PubMed
Publication date: 2026/04/24
Shoemark AmeliaJohnson Emma DShuttleworth MorvenSchwiening MaxHull RebeccaStobo JamieAbo-Leyah HaniFinch SimonPollock JenniferHuang Jeffrey T JRichardson HollianPerea LidiaMcIntosh EveCant ErinGalloway RachelChoi Hayoungde Soyza AnthonySpinou AriettaRingshausen Felix CLorent NatalieMallia PatrickJohnston Sebastian LGierlinski MarekGoeminne PieterLoebinger Michael RHua Gao YongChotirmall Sanjay HDhar RajaHaworth CharlesAltenburg JosjeBlasi FrancescoPolverino EvaShteinberg MichalStrickson SamCipolla DavidTeper ArielFernandez CarlosShih Vivian HMange KevinSinganayagam AranAliberti StefanoSibila OriolLong Merete BChalmers James D - Sepsis-associated acute kidney injury (SA-AKI) is one of the most common and severe complications in clinical practice, with high incidence and mortality rates. This work aimed to demonstrate the predictive value of the inflammatory factors nucleotide-binding oligomerization domain-like receptor protein (NLRP), procalcitonin (PCT), and heparin-binding protein (HBP) for SA-AKI and assess the impact of anti-inflammatory drug therapy on its clinical efficacy. About 120 patients with SA-AKI admitted to our hospital from January 2020 to December 2022 were enrolled, and they were categorized into survival group (82 cases) and death group (38 cases) regarding the outcomes. The levels of NLRP, PCT, and HBP in the blood of both groups were measured, and receiver operating characteristic curves were plotted to evaluate the predictive value of mortality risk factors in SA-AKI patients. The SA-AKI patients received anti-inflammatory drug therapy, and clinical indicators were compared pre- and post-treatment. NLRP, PCT, and HBP in survival group were notably inferior to death group (P < .05). The survival group had greatly inferior acute physiology and chronic health evaluation II scores and sequential organ failure assessment scores to death group (P < .05). NLRP, PCT, and HBP showed positive predictive values for the prognosis of SA-AKI. After anti-inflammatory drug treatment, patients exhibited reduced levels of inflammation, improved renal function, increased urine output, rapid decline in serum creatinine levels, and milder renal injury (P < .05). The anti-inflammatory treatment exhibited a significantly higher overall efficacy rate in patients compared to those for whom the treatment was ineffective (P < .05). NLRP, PCT, and HBP, as inflammatory factors, have high predictive value for the early diagnosis and evaluation of SA-AKI. Anti-inflammatory drug therapy effectively reduces inflammation levels, improves renal function, and mitigates kidney damage in patients. - Source: PubMed
Fang ZhidongCui ShuqinLiu XianShi MinZheng WeiXue JingChen Li - Diabetic kidney disease (DKD) is a severe complication of diabetes mellitus and the leading cause of chronic kidney disease worldwide. Among the many drivers of tubular injury, lipid accumulation and inflammation are emerging as major contributors to kidney disease progression, but the molecular link between lipid metabolism and inflammatory signaling remains to be determined. - Source: PubMed
Publication date: 2026/02/07
Meadows KieranChung HyunjaeVo SonImanzadeh AysaSeo HeewonBelay Sisay GetieSwamy AshaTeo WulinChapman KevinAndonegui GracielaBenediktsson HallgrimurStys Peter KPham ThangMuruve Daniel AChun Justin - To assess the diagnostic efficacy of serum heparin-binding protein (HBP) as a standalone biomarker and in combination panels for distinguishing early-stage bacterial from viral pneumonia, and to explore its prognostic value in predicting progression to severe pneumonia. - Source: PubMed
Publication date: 2026/01/31
Cao PengjuZhang SonggaoHuang JiangangDai Wanru - This research aimed to explore the potential role of heparin-binding protein (HBP) as a prognostic biomarker for adverse events among individuals diagnosed with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (pPCI). - Source: PubMed
Publication date: 2026/01/30
Wang YueyingZhu TianqiZhang WenliZhang RuiyanXie HongyangQu XuezhengBuayiximu KeremuZhu ZhengbinNi JingweiDu RunZhu JinzhouWang XiaoqunDing FenghuaYan XiaoxiangLi PingXu ZhihongQuan Weiwei